NASDAQ:BTTC

Black Titan Q2 2026 Earnings Results & Report

Black Titan logo
$0.26 0.00 (-0.72%)
Closing price 04:00 PM Eastern
Extended Trading
$0.26 0.00 (-0.69%)
As of 06:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Black Titan reported Q2 2026 earnings on June 12, 2026. The company reported EPS of -$0.2240, while revenue was $589.87 thousand.

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
After Market Closes

Black Titan EPS Results

Actual EPS
-$0.2240
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Black Titan Revenue Results

Actual Revenue
$589.87 thousand
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Black Titan Q2 2026 Earnings FAQ

Black Titan (NASDAQ:BTTC) reported earnings of -$0.2240 per share for Q2 2026. The report was announced on Friday, June 12, 2026.

Black Titan reported revenue of $589.87 thousand for Q2 2026.

Black Titan Earnings Headlines

Black Titan Corp (BTTC)
Buy Stocks… A Crash is Coming
Think stocks are expensive and a crash is coming? Economist Jim Rickards says you're right, but he urges investors not to sell before hearing his 2027 prediction. He warns that by November 30th, Congress is set to make a move he believes will trigger a historic buying panic. Economists call the phenomenon a crack-up boom. Rickards is known for correctly predicting the biggest market shocks of the last 20 years.tc pixel
Black Titan Corp BTTC
See More Black Titan Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Black Titan? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Black Titan and other key companies, straight to your email.

About Black Titan

Titan Pharmaceuticals, Inc. is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.

View Black Titan Profile